Freemont Management’s NVIDIA NVDA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$32.9M Sell
188,600
-19,400
-9% -$3.56M 4.98% 1
2025
Q4
$38.8M Buy
208,000
+137,400
+195% +$25.6M 6.77% 1
2025
Q3
$13.2M Sell
70,600
-324,800
-82% -$56.6M 6.59% 2
2025
Q2
$62.5M Buy
395,400
+245,800
+164% +$30.9M 9.36% 1
2025
Q1
$16.2M Buy
149,600
+38,100
+34% +$4.83M 5.33% 1
2024
Q4
$15M Hold
111,500
6.53% 1
2024
Q3
$13.5M Buy
111,500
+4,500
+4% +$532K 6.63% 2
2024
Q2
$13.2M Sell
107,000
-225,000
-68% -$22.7M 6.24% 4
2024
Q1
$30M Sell
332,000
-438,000
-57% -$31.7M 4.28% 4
2023
Q4
$38.1M Buy
+770,000
New +$35.7M 4.8% 3
2022
Q2
Sell
-384,800
Closed -$10.5M 141
2022
Q1
$10.5M Sell
384,800
-172,000
-31% -$4.31M 1.59% 16
2021
Q4
$16.4M Hold
556,800
4.31% 5
2021
Q3
$11.5M Hold
556,800
1.52% 18
2021
Q2
$11.1M Sell
556,800
-140,000
-20% -$2.24M 1.6% 17
2021
Q1
$9.3M Hold
696,800
1.52% 24
2020
Q4
$9.1M Buy
+696,800
New +$9.33M 1.69% 26

Other funds holding NVDA

Freemont Management's NVDA Position: Q1 2026 in Review

Freemont Management reduced its NVIDIA (NVDA) stake by 9.3% in Q1 2026, selling an estimated $3.56M and leaving 188,600 shares worth $32.9M. The position accounts for 4.98% of the portfolio, ranked #1.

Freemont Management first reported a position in NVDA in Q4 2020 and has held it in 16 quarters since. The position peaked at $62.5M in Q2 2025. 5,826 funds tracked by Wall St. Rank hold NVDA as of Q1 2026.

  • Freemont Management held 188,600 shares of NVIDIA worth $32.9M as of Q1 2026.
  • Freemont Management sold 19,400 NVIDIA shares in Q1 2026, an estimated $3.56M.
  • NVIDIA made up 4.98% of Freemont Management's portfolio in Q1 2026, its #1 holding.
  • Freemont Management first reported a position in NVIDIA in Q4 2020 and has held it in 16 quarters since.
  • Freemont Management's NVIDIA position peaked at $62.5M in Q2 2025.
  • 5,826 funds tracked by Wall St. Rank held NVIDIA as of Q1 2026.

Based on Freemont Management's 13F filing for Q1 2026, filed 6 May 2026.